Home › Trials › NCT07255378

Using vasopressin as a second vasopressor in adult septic shock patients

Use of Vasopressin in Septic Shock.

Hospital General Universitario Gregorio Marañon · NCT07255378

This observational project will see if starting vasopressin earlier, based on the norepinephrine dose, helps adults in ICUs with septic shock.

Quick facts

Study typeObservational
Enrollment1200 (estimated)
Ages18 Years and up
SexAll
SponsorHospital General Universitario Gregorio Marañon (other)
Locations12 sites (Terrassa, BARCELONA and 11 other locations)
Trial IDNCT07255378 on ClinicalTrials.gov

What this trial studies

This is a prospective, multicenter observational study of critically ill adults (≥18 years) admitted to ICU with septic shock who receive vasopressin in addition to norepinephrine. Investigators will record the norepinephrine dose at vasopressin initiation and collect daily clinical data during the ICU stay using a pseudonymized REDCap database. The main comparisons focus on timing of vasopressin initiation (defined by norepinephrine dose) and relationships with mortality, renal function, and progression of organ dysfunction. No experimental interventions are assigned — treatments follow local clinical practice and are observed for outcome associations.

Who should consider this trial

Good fit: Adults (age ≥18) admitted to a participating ICU with septic shock who require norepinephrine and receive vasopressin as an adjunct, and who are not excluded by pregnancy, ischemic cardiogenic shock, acute intestinal ischemia, or ICU readmission, are eligible.

Not a fit: Patients who are pediatric, never require vasopressors, have primary ischemic cardiogenic shock, are pregnant, have acute intestinal ischemia, or are ICU readmissions are not expected to benefit from inclusion in this observational project.

Why it matters

Potential benefit: If earlier vasopressin initiation is linked to lower death or less kidney and organ injury, the findings could help clinicians choose the best timing for adding vasopressin and improve outcomes.

How similar studies have performed: Prior randomized trials (for example VASST and VANISH) have tested vasopressin as an adjunct vasopressor with mixed results, leaving the optimal timing and subgroup benefits uncertain.

Eligibility criteria

Show full inclusion / exclusion criteria 
Eligible patients for this study must comply with the following requirements.

* ICU admission with a septic shock diagnosis.
* Age 18 years or above at ICU admission.
* Use of vasopressin as an adjunct of norepinephrine.

For the purposes of this study, septic shock is defined by full compliance with the following criteria.

* Sustained arterial hypotension or serum lactate above 2 mmol/L.
* Adequate but unsuccessful fluid resuscitation.
* Vasopressor usage to maintain a mean arterial pressure above 65 mmHg.
* Probable or proven infectious etiology.

Patients with some of the following conditions will be automatically excluded.

* Pregnancy.
* Ischemic cardiogenic shock.
* Acute intestinal ischemia.
* Readmission to the Intensive Care Unit.

Where this trial is running

Terrassa, BARCELONA and 11 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Septic Shock, Norepinephrine, Dose Threshold, Intensive Care Unit, Arginine Vasopressin Initiation

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.